Key result
CCM improves exercise tolerance, quality of life, and reduces HF hospitalizations in selected HFrEF patients.
Why the study?
Cardiac resynchronization therapy is detrimental in patients with HFrEF and QRS duration less than 120 ms, creating a need for effective device therapies in this underserved population.
Does cardiac contractility modulation improve symptoms and clinical outcomes in patients with HFrEF and QRS duration less than 120 ms?
Design
Review
Authors
Loading...
May support CCM for narrow-QRS HFrEF ineligible for CRT; leaves open confirmation in larger randomized trials.
Does cardiac contractility modulation improve symptoms and clinical outcomes in patients with HFrEF and QRS duration less than 120 ms?
Cardiac contractility modulation provides a beneficial device-based therapeutic option for patients with HFrEF and narrow QRS who are ineligible for cardiac resynchronization therapy.
Haloot et al. (2023) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Cardiac contractility modulation (CCM) was evaluated. Cardiac contractility modulation is a beneficial device-based therapy for selected patients with HFrEF, improving exercise tolerance, quality of life, and reducing heart failure hospitalizations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: